Synergistic drug combinations prediction by integrating pharmacological data
暂无分享,去创建一个
[1] Xing Chen,et al. NLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised Learning , 2016, PLoS Comput. Biol..
[2] Steven T. Nakajima,et al. Norethindrone Acetate 1.0 Milligram and Ethinyl Estradiol 10 Micrograms as an Ultra Low-Dose Oral Contraceptive , 2013, Obstetrics and gynecology.
[3] Abid Ahmad Sofi,et al. Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. , 2012, Asian Pacific journal of cancer prevention : APJCP.
[4] Xin Chen,et al. DCDB: Drug combination database , 2010, Bioinform..
[5] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[6] Edmund Luo,et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. , 2009, Current medical research and opinion.
[7] P. Peduzzi,et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. , 2013, The New England journal of medicine.
[8] R. Frederich,et al. Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin , 2013, International journal of clinical practice.
[9] Donald A. Smith,et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study. , 2006, American heart journal.
[10] A. Genazzani,et al. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. , 2001, American journal of obstetrics and gynecology.
[11] Melanie J. Davies,et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study , 2009, Current medical research and opinion.
[12] Sándor Pongor,et al. Predicting effective drug combinations via network propagation , 2013, 2013 IEEE Biomedical Circuits and Systems Conference (BioCAS).
[13] Yoshihiro Yamanishi,et al. Large-Scale Prediction of Beneficial Drug Combinations Using Drug Efficacy and Target Profiles , 2015, J. Chem. Inf. Model..
[14] Chih-Jen Lin,et al. Field-aware Factorization Machines for CTR Prediction , 2016, RecSys.
[15] Zhiyong Lu,et al. A survey of current trends in computational drug repositioning , 2016, Briefings Bioinform..
[16] Wei Li,et al. Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles , 2017, Artif. Intell. Medicine.
[17] Yi Xiong,et al. Prediction of Effective Drug Combinations by an Improved Naïve Bayesian Algorithm , 2018, International journal of molecular sciences.
[18] Susumu Goto,et al. LIGAND: database of chemical compounds and reactions in biological pathways , 2002, Nucleic Acids Res..
[19] Michael Noonan,et al. Efficacy and Safety of Budesonide and Formoterol in One Pressurised Metered-Dose Inhaler in Adults and Adolescents with Moderate to Severe Asthma , 2012, Drugs.
[20] Xing Chen,et al. ASDCD: Antifungal Synergistic Drug Combination Database , 2014, PloS one.
[21] Qiuhong Wang,et al. Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome , 2016, Scientific Reports.
[22] M. Dickson,et al. The cost of new drug discovery and development. , 2004, Discovery medicine.
[23] J. Gustafsson,et al. Progesterone receptor-estrogen receptor crosstalk: a novel insight , 2015, Trends in Endocrinology & Metabolism.
[24] Xing-Ming Zhao,et al. Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data , 2011, PLoS Comput. Biol..
[25] L. Mansfield,et al. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma. , 2013, Respiratory medicine.
[26] Lei Chen,et al. Prediction of Effective Drug Combinations by Chemical Interaction, Protein Interaction and Target Enrichment of KEGG Pathways , 2013, BioMed research international.
[27] R. DeFronzo,et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. , 2012, The Journal of clinical endocrinology and metabolism.
[28] Roland Chen,et al. Efficacy and Safety of Saxagliptin Combination Therapy in US Patients with Type 2 Diabetes , 2011, Postgraduate medicine.
[29] Ting-I Lee,et al. The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes. , 2013, International journal of cardiology.
[30] Xiaohua Ma,et al. Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.
[31] David R Owens,et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial , 2012, The Lancet.
[32] Kirsten McAulay,et al. Efficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: a randomised controlled trial , 2013, Current medical research and opinion.
[33] Ting-Chao Chou,et al. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.
[34] R. Pratley,et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study , 2009, Current medical research and opinion.
[35] Xuelin He,et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. , 2014, JAMA internal medicine.
[36] Mickael Guedj,et al. Analysis of drug combinations: current methodological landscape , 2015, Pharmacology research & perspectives.
[37] Yi Xiong,et al. A Hadoop-Based Method to Predict Potential Effective Drug Combination , 2014, BioMed research international.
[38] Di Chen,et al. Systematic synergy modeling: understanding drug synergy from a systems biology perspective , 2015, BMC Systems Biology.
[39] Xiu-Jie Zhou,et al. [Homoharringtonine combined arsenic trioxide induced apoptosis in human multiple myeloma cell line RPMI 8226: an experimental research]. , 2013, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.
[40] Lai Wei,et al. Analysis and prediction of drug–drug interaction by minimum redundancy maximum relevance and incremental feature selection , 2017, Journal of biomolecular structure & dynamics.
[41] Chih-Jen Lin,et al. Training and Testing Low-degree Polynomial Data Mappings via Linear SVM , 2010, J. Mach. Learn. Res..
[42] E. Papanikolaou,et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. , 2013, Human reproduction.
[43] Stefan Peterson,et al. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD. , 2010, Respiratory medicine.
[44] B. Schwab,et al. Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler. , 2011, Respiratory medicine.
[45] Roland Chen,et al. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus , 2011, Diabetes & vascular disease research.
[46] P. Amouyel,et al. Association of angiotensin converting enzyme and angiotensin II type 1 receptor genotypes with left ventricular function and mass in patients with angiographically normal coronary arteries. , 1997, Heart.